A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Research

Executive Summary: A 83-01 is a small-molecule inhibitor targeting TGF-β type I receptor ALK-5, with additional activity against ALK-4 and ALK-7, suppressing Smad-dependent transcription with nanomolar potency (APExBIO). In vitro, it reduces ALK-5-mediated luciferase reporter activity by 68% at 1 μM in Mv1LuR4-2 cells. It is highly selective, not significantly affecting BMP-induced transcription at ≤1 μM. A 83-01 is validated for use in EMT, cancer, fibrosis, and trophoblast differentiation models (Anvar et al., 2024). Its solubility, purity, and storage parameters are optimized for reproducible research workflows.

Biological Rationale

TGF-β signaling is a central regulator of cell growth, differentiation, and epithelial-mesenchymal transition (EMT) in development and disease. Dysregulation of this pathway contributes to cancer progression, fibrosis, and impaired stem cell differentiation (Anvar et al., 2024). The TGF-β type I receptor, also known as activin receptor-like kinase 5 (ALK-5), initiates Smad2/3 phosphorylation upon ligand binding, leading to transcriptional responses. Small-molecule ALK-5 inhibitors such as A 83-01 enable precise blockade of this pathway, allowing researchers to interrogate the roles of TGF-β/Smad signaling in diverse biological contexts.

Mechanism of Action of A 83-01 (ALK inhibitor)

A 83-01 (3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide) is a selective ATP-competitive inhibitor of ALK-5, with additional inhibitory activity against ALK-4 and ALK-7. Its IC₅₀ for ALK-5 is approximately 12 nM in biochemical assays (APExBIO). In cellular systems, A 83-01 blocks TGF-β-induced phosphorylation of Smad2/3, suppressing canonical TGF-β/Smad signaling. At 1 μM, A 83-01 reduces ALK-5-driven luciferase reporter activity by 68% in Mv1LuR4-2 cells. It does not significantly inhibit BMP-induced (Smad1/5/8 pathway) transcription at this concentration, indicating selectivity for the TGF-β/activin/nodal branch. Only at concentrations above 3 μM does weak suppression of BMP4-induced activity occur (APExBIO).

Evidence & Benchmarks

• A 83-01 inhibits ALK-5-mediated Smad-dependent transcription in Mv1LuR4-2 cells with an IC₅₀ of 12 nM (APExBIO).
• At 1 μM, A 83-01 reduces ALK-5-induced luciferase reporter activity by 68% in vitro (APExBIO).
• In human ESC differentiation protocols, inclusion of A 83-01 (0.5–1 μM) with BMP4 and FGF2 inhibitor PD173074 suppresses mesoderm and endoderm formation, and enhances trophoblast specification, as measured by upregulation of CDX2 and KRT7 markers (Anvar et al., 2024).
• A 83-01 demonstrates >98% purity by HPLC, MS, and NMR, supporting reproducibility and low batch variability (APExBIO).
• It is soluble at ≥21.1 mg/mL in DMSO and ≥9.82 mg/mL in ethanol (with warming/sonication), but insoluble in water (APExBIO).
• Protocols using A 83-01 in combination with BMP4 and PD173074 enable efficient trophoblast lineage induction in hESCs, as evidenced by HLA-G protein expression and reduced pluripotency marker levels by day 7 (Anvar et al., 2024).

This article extends the overview in A 83-01: Precision ALK-5 Inhibitor Enhancing Intestinal Organoid Modeling by presenting detailed quantitative benchmarks and best practices for stem cell and trophoblast lineage applications.

For further mechanistic insights, see A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Research, which reviews atomic facts and integration strategies, while this dossier provides direct experimental context from recent peer-reviewed studies.

Applications, Limits & Misconceptions

• EMT and cancer biology: A 83-01 is used to study TGF-β-driven EMT, tumor invasion, and growth inhibition by blocking Smad2/3 activation (A 83-01: Selective ALK-5 Inhibitor for Advanced TGF-β Pathway Research).
• Stem cell differentiation: Inclusion of A 83-01 in differentiation media suppresses mesendodermal fates, favoring trophoblast or epithelial outcomes (Anvar et al., 2024).
• Organoid modeling: It enables robust expansion of epithelial organoids by preventing TGF-β-mediated growth arrest and EMT (A 83-01: Precision ALK-5 Inhibitor Enhancing Intestinal Organoid Modeling).
• Fibrosis models: Used as a tool to block TGF-β-induced profibrotic gene expression in vitro (Strategic Modulation of TGF-β Signaling).
• Note: A 83-01 is not recommended for in vivo therapeutic use; its role is restricted to research applications (APExBIO).

Common Pitfalls or Misconceptions

• A 83-01 does not inhibit BMP-induced Smad1/5/8 signaling at ≤1 μM; off-target effects may appear only at higher concentrations.
• It is not water soluble; improper solvent use can lead to precipitation or assay failure.
• Long-term storage of stock solutions (in DMSO/ethanol) at room temperature reduces potency; stocks should be aliquoted and stored below -20°C.
• Not suitable for direct in vivo administration; validated use is strictly in vitro.
• Incomplete inhibition of ALK-4/ALK-7 at standard concentrations may leave some activin/nodal signaling intact.

Workflow Integration & Parameters

Preparation: Dissolve A 83-01 in DMSO to a stock concentration of ≥21.1 mg/mL. Warm at 37°C for 10 minutes or sonicate to improve solubility. For ethanol, dissolve up to 9.82 mg/mL with gentle warming/ultrasonication. Use only freshly prepared or properly stored stocks (≤-20°C).

Assay Conditions: Typical working concentrations are 0.5–1 μM for in vitro cell signaling assays and stem cell differentiation protocols (Anvar et al., 2024). Avoid concentrations >3 μM unless low selectivity is acceptable. For luciferase reporter assays, preincubate cells for 30–60 minutes with A 83-01 before ligand stimulation.

Experimental Design: Use as a component in dual-inhibition protocols (e.g., with PD173074 for FGF2 inhibition) for lineage specification studies. Validate inhibition by monitoring p-Smad2/3 or reporter gene output.

This article clarifies the application boundaries and solubility requirements not fully detailed in A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Research.

Conclusion & Outlook

A 83-01, from APExBIO, is a benchmark selective inhibitor of ALK-5 with robust, well-validated performance metrics for TGF-β/Smad pathway research. Its defined selectivity, nanomolar potency, and compatibility with in vitro models make it a gold standard for studies in EMT, cancer, fibrosis, and stem cell biology. Ongoing refinements in differentiation and organoid protocols continue to reveal new utility for A 83-01 as a research tool. For further product details and ordering information, see the A 83-01 (ALK inhibitor) product page.